GSK
Price
$38.28
Change
-$0.40 (-1.03%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
88.13B
35 days until earnings call
JNJ
Price
$152.32
Change
+$0.13 (+0.09%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
380.22B
21 days until earnings call
Interact to see
Advertisement

GSK vs JNJ

Header iconGSK vs JNJ Comparison
Open Charts GSK vs JNJBanner chart's image
GSK
Price$38.28
Change-$0.40 (-1.03%)
Volume$39.51K
Capitalization88.13B
Johnson & Johnson
Price$152.32
Change+$0.13 (+0.09%)
Volume$60.37K
Capitalization380.22B
GSK vs JNJ Comparison Chart in %
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. JNJ commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and JNJ is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (GSK: $38.68 vs. JNJ: $152.19)
Brand notoriety: GSK: Not notable vs. JNJ: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 94% vs. JNJ: 123%
Market capitalization -- GSK: $88.13B vs. JNJ: $380.22B
GSK [@Pharmaceuticals: Major] is valued at $88.13B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $380.22B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 0 green FA rating(s).

  • GSK’s FA Score: 1 green, 4 red.
  • JNJ’s FA Score: 0 green, 5 red.
According to our system of comparison, both GSK and JNJ are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 6 TA indicator(s) are bullish while JNJ’s TA Score has 5 bullish TA indicator(s).

  • GSK’s TA Score: 6 bullish, 4 bearish.
  • JNJ’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GSK is a better buy in the short-term than JNJ.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -2.62% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -0.12% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.52%. For the same industry, the average monthly price growth was +4.77%, and the average quarterly price growth was +8.25%.

Reported Earning Dates

GSK is expected to report earnings on Jul 30, 2025.

JNJ is expected to report earnings on Jul 16, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.52% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($380B) has a higher market cap than GSK($88.1B). JNJ has higher P/E ratio than GSK: JNJ (30.34) vs GSK (14.01). GSK YTD gains are higher at: 16.959 vs. JNJ (6.986). JNJ has higher annual earnings (EBITDA): 23.3B vs. GSK (9.08B). JNJ has more cash in the bank: 22.9B vs. GSK (4.99B). GSK has less debt than JNJ: GSK (18B) vs JNJ (29.3B). JNJ has higher revenues than GSK: JNJ (85.2B) vs GSK (30.3B).
GSKJNJGSK / JNJ
Capitalization88.1B380B23%
EBITDA9.08B23.3B39%
Gain YTD16.9596.986243%
P/E Ratio14.0130.3446%
Revenue30.3B85.2B36%
Total Cash4.99B22.9B22%
Total Debt18B29.3B61%
FUNDAMENTALS RATINGS
GSK vs JNJ: Fundamental Ratings
GSK
JNJ
OUTLOOK RATING
1..100
7269
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
7049
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5355
P/E GROWTH RATING
1..100
2379
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (50) in the Pharmaceuticals Major industry is in the same range as JNJ (50). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.

JNJ's Profit vs Risk Rating (49) in the Pharmaceuticals Major industry is in the same range as GSK (70). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

JNJ's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as GSK (100). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

GSK's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as JNJ (55). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.

GSK's P/E Growth Rating (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (79). This means that GSK’s stock grew somewhat faster than JNJ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKJNJ
RSI
ODDS (%)
Bearish Trend 2 days ago
44%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
45%
Momentum
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
54%
MACD
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
54%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
40%
Advances
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
40%
Declines
ODDS (%)
Bearish Trend 6 days ago
53%
Bearish Trend 6 days ago
43%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
51%
Aroon
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
39%
View a ticker or compare two or three
Interact to see
Advertisement
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JOB0.210.01
+2.79%
GEE Group
SEE31.230.44
+1.43%
Sealed Air Corp
CNNE20.670.04
+0.19%
Cannae Holdings
VZLA2.94-0.07
-2.33%
Vizsla Silver Corp
OXY42.48-1.47
-3.34%
Occidental Petroleum Corp

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+1.10%
NVS - GSK
65%
Loosely correlated
+1.11%
PFE - GSK
60%
Loosely correlated
+1.17%
AZN - GSK
59%
Loosely correlated
-0.14%
AMGN - GSK
54%
Loosely correlated
+1.85%
SNY - GSK
51%
Loosely correlated
+0.50%
More